STERIS stock tumbles 20% despite beating revenue expectations in Q3
STERIS plc, a leading provider of infection prevention products, has faced a challenging few months in the stock market. The Ohio-based company, valued at $21 billion, has seen its share price drop by 20.4% since hitting a 52-week high in January. Despite this recent decline, analysts remain cautiously optimistic about its future performance.
STERIS specialises in infection control, offering a wide range of products from sterilizers and washers to surgical tables and endoscopy accessories. Its mix of consumables and capital equipment has helped it become a key player in the medical device sector.
Over the past year, STERIS stock rose by 20.18%, outperforming competitors like Terumo Corporation, which saw a 15.66% gain. However, the past three months have been tougher. While the Nasdaq Composite fell by 4.7%, STERIS dropped by 14.8%. The company's shares have also stayed below their 200-day moving average since early March and their 50-day average since February.
In its latest financial report, STERIS posted Q3 revenue of $1.50 billion, slightly above analyst expectations of $1.48 billion. Adjusted earnings per share matched forecasts at $2.53. Despite the recent downturn, Wall Street analysts maintain a 'Moderate Buy' rating, with an average price target of $288.43—implying a potential 34.4% upside from current levels.
STERIS continues to hold a strong position in the infection prevention market, though its stock has struggled in recent months. With revenue beating estimates and analysts projecting significant upside, the company's next moves will be closely watched. Rival Stryker Corporation, while down 7.4% over the past year, has fared better than STERIS in the last six months, losing 12.2% compared to STERIS's steeper decline.
